SMI 10’794 3.3%  SPI 13’946 3.4%  Dow 31’501 2.7%  DAX 13’118 1.6%  Euro 1.0120 0.0%  EStoxx50 3’533 2.8%  Gold 1’826 0.2%  Bitcoin 20’347 0.4%  Dollar 0.9589 -0.3%  Öl 113.1 3.0% 

BioDelivery jetzt einsteigen?

Seite 1 von 1
neuester Beitrag: 10.08.19 21:39
eröffnet am: 11.03.16 21:20 von: martin30sm Anzahl Beiträge: 4
neuester Beitrag: 10.08.19 21:39 von: Biotecfan Leser gesamt: 9542
davon Heute: 1
bewertet mit 0 Sternen

11.03.16 21:20

4601 Postings, 6310 Tage martin30smBioDelivery jetzt einsteigen?

14.03.16 12:55

4601 Postings, 6310 Tage martin30smNews

BioDelivery Sciences to Present Today at the 28th Annual ROTH Conference

12:05 14.03.16

PR Newswire

RALEIGH, N.C., March 14, 2016

RALEIGH, N.C., March 14, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 28th Annual ROTH Conference.  The conference, which will be webcast, is scheduled for today, Monday, March 14, 2016, at 9:00 – 9:30 AM Pacific Time (12:00 – 12:30 PM Eastern Time).

Dr. Sirgo will provide additional insight into last week's forth quarter and end of year earnings call, as well as progress with BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and strategies supporting further growth of BUNAVAIL in 2016.  Also discussed will be the recent launch of BELBUCA™ (buprenorphine) buccal film (CIII) by BDSI's commercial partner, Endo Pharmaceuticals.

The presentations will be webcast live and can be accessed at  For those who are not available to listen to the live broadcasts, replay of the webcasts will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.  BDSI's headquarters is located in Raleigh, North Carolina.  

For more information, please visit or follow us:



Twitter:  @BioDeliverySI

BDSI markets BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and ONSOLIS® (fentanyl buccal soluble film) (CII).  BELBUCA™ (buprenorphine) buccal film (CIII) is commercialized in the U.S. by Endo Pharmaceuticals pursuant to the worldwide licensing and development agreement between BDSI and Endo.   For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS, please visit where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit

Cautionary Note on Forward-Looking Statements

This press release, the presentations described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentation described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of commercialization efforts for the Company's approved products and the clinical trials for, and regulatory review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc.  All other trademarks and tradenames are owned by their respective owners.

© 2016 BioDelivery Sciences International, Inc.  All rights reserved.

Logo -

To view the original version on PR Newswire, visit:

SOURCE BioDelivery Sciences International, Inc.
Quelle: PR Newswire  

23.05.18 11:44

6310 Postings, 2364 Tage 1QuantumChart

10.08.19 21:39

812 Postings, 1736 Tage BiotecfanJetzt sehe ich

einen guten Zeitpunkt zum einsteigen, sind jetzt am Breakeven dran und sie haben mit Belbuca ein Medikament das sich gut verkauft .
Mit einer Kapitalerhöhung wurde für 30 Millionen  die Vermarktungsrechte ein weiteres Medikament gekaut, das sich eventuell als Schnäppchen erweisen könnte.
Und zu guter letzt wurde die Schuldenrückzahlung  neu geregelt.
Sie sind jetzt in der Wachstumsphase angekommen

   Antwort einfügen - nach oben